
Katie B Tellor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7650844/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Key Points for Pharmacists From the ACC Expert Consensus Decision Pathway for Patients Hospitalized With Heart Failure. Journal of Pharmacy Practice, 2022, , 089719002110647.	1.0	Ο
2	Evaluation of Guideline-Directed Medical Therapy for the Reduction of Stroke and Systemic Embolism in Hospitalized Patients with Nonvalvular Atrial Fibrillation. Hospital Pharmacy, 2021, 56, 26-31.	1.0	0
3	Flecainide is well-tolerated and effective in patient with atrial fibrillation at 12 months: a retrospective study. Therapeutic Advances in Cardiovascular Disease, 2020, 14, 175394472092682.	2.1	6
4	Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital. Journal of Community Hospital Internal Medicine Perspectives, 2020, 10, 38-44.	0.8	4
5	Evaluation of the Safety and Effectiveness of Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation and Coexisting Valvular Heart Disease. American Journal of Cardiovascular Drugs, 2020, 20, 611-617.	2.2	8
6	Predictors of Student Failure or Poor Performance on Advanced Pharmacy Practice Experiences. American Journal of Pharmaceutical Education, 2020, 84, ajpe7890.	2.1	15
7	Evaluation of the effect of prior antiarrhythmic drug use on the success of atrial fibrillation catheter ablation. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 708-714.	1.5	1
8	A rare case of a gabapentinâ€induced cardiomyopathy. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 644-646.	1.5	6
9	Systematic evaluation of the methodological quality of clinical practice guidelines intended for pharmacists. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 14-25.	1.0	3
10	Evaluation of the impact of body mass index on warfarin requirements in hospitalized patients. Therapeutic Advances in Cardiovascular Disease, 2018, 12, 207-216.	2.1	15
11	Clinical experience reversing factor Xa inhibitors with four-factor prothrombin complex concentrate in a community hospital. Blood Transfusion, 2018, 16, 382-386.	0.4	10
12	Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment. Pharmacotherapy, 2017, 37, 412-419.	2.6	96
13	Evaluation of Apixaban for the Treatment of Nonvalvular Atrial Fibrillation With Regard to Dosing and Safety in a Community Hospital. Journal of Pharmacy Technology, 2017, 33, 140-145.	1.0	4
14	Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin for Venous Thromboembolism Prophylaxis in Hemodialysis Patients. Hospital Pharmacy, 2017, 52, 623-627.	1.0	12
15	Comparison of Clevidipine versus Sodium Nitroprusside for the Treatment of Postoperative Hypertension in Cardiac Surgery Patients. Hospital Pharmacy, 2016, 51, 461-467.	1.0	3
16	Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism. Therapeutics and Clinical Risk Management, 2016, 12, 667.	2.0	0
17	Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 447-451.	1.5	29
18	Edoxaban, a Novel Oral Factor Xa Inhibitor. Annals of Pharmacotherapy, 2015, 49, 843-850.	1.9	12

#	Article	IF	CITATIONS
19	Extended-Duration Venous Thromboembolism Prophylaxis in Hospitalized Acutely III Medical Patients. Journal of Pharmacy Technology, 2015, 31, 228-233.	1.0	0